CBG properties and effects: how does it differ from CBD and who is it better for

For a long time, CBD was the only cannabinoid that received significant attention. Now, CBG — cannabigerol — is entering the conversation, described by scientists as the 'mother of all cannabinoids' and gaining increasing interest from both researchers and cannabis supplement users. How does CBG differ from CBD? Does it work better, differently, what is it intended for? And is it worth choosing it instead of or alongside CBD? This article answers these questions based on available research.

KEY INFORMATION
• CBG (cannabigerol) is a biological precursor to CBD and THC in the cannabis plant — CBGA is the 'mother' of all major cannabinoids (Nachnani et al., Biomolecules, 2021).
• CBG binds directly to CB1 and CB2 receptors (unlike CBD, which acts indirectly).
• CBG exhibits neuroprotective, antibacterial properties (including against MRSA) and potentially enhances focus.
• CBD acts more strongly anxiolytically and anti-inflammatorily; CBG is described as more 'energizing' and supportive of concentration.
• Products combining CBD and CBG may provide synergistic effects through the entourage effect.

What is CBG – where does it come from in the hemp plant?

CBG (cannabigerol) is a biochemical precursor to all major cannabinoids in the cannabis plant. Synthesis begins with cannabigerolic acid (CBGA) — this is the starting compound from which CBDA (→CBD), THCA (→THC), and CBCA (→CBC) are enzymatically produced. The cannabis plant 'chooses' how much of each of these precursors to convert — meaning that CBD-rich strains contain relatively little CBGA (as most is converted to CBDA), while specially bred 'high-CBG' strains have limited conversion enzymes and retain more cannabigerol.

Review by Nachnani et al. (Biomolecules, 2021) described CBG as a 'parent cannabinoid' and summarized the current state of research. The authors identified CBG's action on: CB1 and CB2 receptors (partial agonism), serotonin receptors 5-HT1A (antagonism — which may paradoxically enhance the effectiveness of CBD on the same receptors), alpha-2 adrenergic receptors (blocking), and TRPM8 calcium channels. This multifaceted pharmacological profile distinguishes CBG from CBD and gives it a different, complementary mode of action.

Historically, CBG was present in cannabis products only as a trace component of full spectrum — because typical industrial hemp strains contain only 0.1–1% CBG. Increased interest has led to the cultivation of 'high-CBG' strains containing up to 10–15% CBG and virtually no THC — which has enabled the production of CBG isolate and oils concentrated on cannabigerol.

Mechanism of action of CBG – how does it differ from CBD?

Understanding the difference in the mechanisms of action of CBD and CBG helps to understand why their effects are different and complementary.

CBD acts mainly indirectly: it does not bind to CB1 or CB2 as a primary target, but modulates their activity by inhibiting the enzyme FAAH (which degrades anandamide — an endogenous cannabinoid), through TRPV1 receptors (pain, temperature), serotonin transporters SERT, and PPARγ receptors. The effect of CBD is thus a broad modulation of homeostasis, where no single target is critical.

CBG acts more directly: it is a partial agonist of CB1 and CB2 receptors, a strong inhibitor of norepinephrine reuptake (by blocking alpha-2 adrenergic receptors), and an antagonist of 5-HT1A receptors. Blocking alpha-2 norepinephrine may explain the observed stimulating and concentration-supporting effects — as alpha-2 inhibition increases norepinephrine release in the prefrontal cortex, which is a mechanism similar to that of some ADHD medications.

The antagonism of 5-HT1A by CBG is interesting for another reason: while CBD is an agonist of 5-HT1A (which explains its anxiolytic effects), CBG as an antagonist may block the same receptor — suggesting that CBG and CBD act on serotonin differently. Together, a CBD-dominant full spectrum oil with trace CBG may modulate the serotonin system from several angles simultaneously, yielding different effects than each alone.

Properties of CBG – what do studies say?

Research on CBG is at an earlier stage than research on CBD — most data comes from animal models and in vitro studies, and there are fewer randomized clinical trials in humans. However, the direction of research is clear and indicates several areas where CBG may have significant clinical relevance.

Neuroprotection and neurodegeneration: One of the most promising applications of CBG is the protection of neurons from degeneration. Valdeolivas et al. (Neurotherapeutics, 2015) demonstrated that CBG protected motor neurons in a model of amyotrophic lateral sclerosis (ALS) in mice, slowing disease progression and improving motor functions. Esposito et al. (Neurotherapeutics, 2015) described the neuroprotective effects of CBG in a model of Huntington's disease.

Antibacterial action: CBG exhibits strong antibiotic activity, including against methicillin-resistant strains (Staphylococcus aureus — MRSA). Farha et al. (ACS Infectious Diseases, 2020) described CBG as a 'compound with antibiotic activity comparable to vancomycin' against MRSA in vitro. This is one of the rare cases where a cannabinoid exhibits pharmacological activity that is distinctly different and potentially stronger than CBD.

Inflammatory bowel conditions: Borrelli et al. (Biochemical Pharmacology, 2013) demonstrated that CBG reduced inflammation in a colitis model in mice (by decreasing the expression of pro-inflammatory cytokines IL-1β and TNF-α) and improved intestinal barrier integrity. Human studies — none yet, but preclinical data is consistent and justifies further research.

Cognitive functions and concentration: By blocking alpha-2 adrenergic receptors and antagonizing 5-HT1A, CBG may exhibit effects that support alertness and concentration. Preliminary user reports (informal) describe CBG as 'energizing' in contrast to CBD, which is often described as more 'calming'. Clinical studies on this property are ongoing.

CBG vs CBD – practical comparison of effects

How do these mechanisms translate into practical differences in sensations and indications? Below is a synthetic comparison based on research data and clinical descriptions.

Anxiety and stress: CBD has a clear advantage. As a 5-HT1A agonist and FAAH inhibitor, CBD increases the concentration of anandamide (the endogenous 'cannabinoid prozac') and activates the serotonin receptor with anxiolytic effects. CBG, as a 5-HT1A antagonist, may even weaken the anxiolytic effect of CBD when there is a high proportion of CBG in the mixture. In cases of anxiety and stress: choose a CBD-dominant product.

Concentration and focus during the day: CBG may have the upper hand. The adrenergic mechanism (alpha-2 inhibition) and lack of sedative effects make CBG an interesting candidate for supporting conceptual work. CBD at low doses is sometimes described as gently stimulating, but at higher doses — relaxing and potentially slowing reactions. For concentration: consider a CBG-dominant oil or low-dose CBD.

Inflammatory bowel conditions: CBG has stronger preclinical data than CBD for inflammatory bowel diseases — the CB2 mechanism in intestinal tissues and reduction of IL-1β are well documented for CBG. CBD also exhibits anti-inflammatory effects, but more through PPAR-γ and TRPV1. For bowel issues: CBG or a mixture.

Neuropathic pain: CBD is stronger — TRPV1 and SERT give CBD a clear advantage in neuropathic pain. CBG complements through CB2 and alpha-2 adrenergic, but as a main substance, it is less well documented for pain. For pain: CBD as the main, CBG as a supplement.

Amyotrophic lateral sclerosis and neurodegenerative diseases: CBG has more direct data — studies on ALS and Huntington's described CBG, not CBD, as the main neuroprotective factor. This is an area of clinical research still in the pilot phase.

Can CBG be combined with CBD?

The combination of CBG and CBD is not only safe but potentially beneficial due to the synergistic effect between these cannabinoids. Pamplona et al. (Frontiers, 2020) demonstrated that multi-component extracts work more effectively than isolates — and CBG is one of the key components creating this synergy in full spectrum oils.

Popular ratios in CBD+CBG products on the market: 3:1 (CBD:CBG) — provides more anxiolytic CBD with an 'energizing' touch of CBG; 1:1 — equivalent, experimental, for those seeking stronger CBG effects; 5:1 or more CBD — standard full spectrum oils with natural trace CBG. There are no precise clinical studies yet determining the optimal ratio for specific indications — so treat this as an area for experimentation, not an established norm.

Our observations: Users interested in CBG often describe it as 'CBD for morning energy' as opposed to 'CBD for evening relaxation'. Those who have tried CBD for pain and were not fully satisfied with the effect sometimes find better relief with full spectrum oils containing more CBG — which is consistent with the entourage effect theory. This is an area where individual experimentation with journaling yields better results than trying to find a single universal answer.

CBG and cancer – preliminary research findings

Research on CBG and cancer cells is preliminary and almost exclusively in vitro (in cell cultures), so clinical conclusions cannot be drawn. Nevertheless, it is worth noting. Borrelli et al. (Carcinogenesis, 2014) demonstrated that CBG inhibits the proliferation of colorectal cancer cells in vitro and in a mouse model. The mechanism involved blocking cannabinoid receptors in cancer cells and inducing apoptosis. This finding is consistent with the broader literature on cannabinoids as potential anti-proliferative agents — but requires confirmation in clinical studies in humans, which are lacking.

Similar preliminary data have been described regarding breast cancer and prostate cancer in in vitro models. We emphasize: none of these results provide a basis for using CBG as a cancer therapy — this is a stage for formulating hypotheses for further research. Individuals affected by cancer should discuss all supplements, including CBG, with their oncologist before incorporating them.

CBG dosage – how much to take and how to use it?

Clinical studies on CBG are still preliminary and do not provide precise dosing protocols comparable to CBD. A cautious heuristic based on available data: for CBG isolate or CBG-dominant products, the starting point is 5–15 mg/day — similar to CBD. Divided dosing (in the morning, especially with concentration support) makes sense due to the stimulating profile of CBG. An evening dose of CBG may be less advisable for those sensitive to stimulation.

With products combining CBD and CBG (full spectrum or dedicated blends): dosing starts from the CBD content — you follow the standard CBD dosing protocol, and CBG comes 'in the package'. There is no evidence that trace amounts of CBG in full spectrum require dose adjustment. For products with a higher CBG content (e.g., 30–50% CBG): start with 5 mg of CBG daily and observe effects for a week before increasing. A detailed comparison of CBD oils available in Poland can be found in the article. CBD Oil Ranking 2026.

CBG and glaucoma – intriguing preliminary data

One of the particularly interesting potential applications of CBG concerns glaucoma — a disease leading to vision loss due to excessive intraocular pressure. Colasanti et al. (Journal of Ocular Pharmacology, 1984) demonstrated in early studies that cannabinoids, including CBG, lower intraocular pressure in cats. CBG may act through CB1 receptors in ocular tissue and adrenergic mechanisms regulating aqueous humor production.

Important note: research on CBG and glaucoma is preliminary and involves animal models or early pilot studies. There is insufficient evidence from large clinical trials in humans to recommend CBG as a treatment for glaucoma. However, this area of research distinguishes CBG from other cannabinoids and indicates potential ophthalmic applications that would not be achievable with CBD alone. In cases of glaucoma — always under the supervision of an ophthalmologist.

CBG safety – is it as safe as CBD?

Direct safety data on CBG in humans is less than for CBD, but data from in vitro and animal studies suggest a similarly favorable safety profile. CBG is not a psychoactive substance, does not cause addiction, nor withdrawal symptoms in animal models. Nachnani et al. (Biomolecules, 2021) described CBG as a 'cannabinoid with a favorable safety profile without psychoactive properties'.

Drug interactions: data is limited. CBG may be metabolized by CYP enzymes — similar to CBD — which potentially means similar interaction risks. When using prescription medications, especially anticoagulants, epilepsy medications, or immunosuppressants, consulting a physician is as important as with CBD. Regarding drug tests: CBG is not a substance sought by standard tests — there is no risk of a positive test regardless of the dose.

Frequently Asked Questions

What is CBG and how does it work?

CBG (cannabigerol) is a plant cannabinoid that serves as a biological precursor to CBD and THC. It acts as a partial agonist of CB1 and CB2, an antagonist of 5-HT1A receptors, and a norepinephrine reuptake inhibitor. Research Nachnani et al. (Biomolecules, 2021) indicates neuroprotective, antibacterial properties (including against MRSA), and potentially concentration-supporting effects.

What is the difference between CBG and CBD?

CBD modulates the endocannabinoid system mainly indirectly (TRPV1, SERT, PPAR-γ); CBG binds directly to CB1 and CB2. CBD acts more strongly anxiolytically and anti-inflammatorily; CBG is described as more 'energizing' and neuroprotective. CBG is a biochemical precursor to CBD in the plant — CBGA produces both CBDA and THCA.

Is CBG psychoactive?

No — CBG does not produce a psychoactive effect or a high. It is not a narcotic or psychotropic substance in Poland and the EU. Clinical studies have not reported any disturbances in perception or psychomotor abilities after CBG.

Who should choose CBG instead of CBD?

CBG may be a better choice for those seeking support for concentration and focus during the day, for inflammatory bowel conditions (preclinical data Borrelli et al., 2013), for neuropathic pain as a supplement to CBD, or for those who tolerate CBD well but are looking for an additional energizing effect.

Can CBG be combined with CBD?

Yes — this is a popular and potentially beneficial approach. Products combining CBD and CBG may provide synergistic effects: CBD is anxiolytic and anti-inflammatory, while CBG is neuroprotective and supports focus. There are no large RCTs for specific ratios, but the entourage effect between CBD and CBG is confirmed in preclinical studies.

This article is for informational and educational purposes and does not constitute medical advice. Before starting to use cannabis or CBD for therapeutic purposes, consult a doctor, especially if you are taking other medications, are pregnant, or breastfeeding.

Author: Michał Waluk · Published: 2026-05-04 · Updated: 2026-05-04